LG Group’s plan to name its new holding company “LX” faces a setback as another company threatens legal action to stop the move, claiming rights over the name. The state-run Land and Geospatial Informatix Corporation announced Tuesday that it would take legal action against LG Group to prevent the South Korean conglomerate from using its trade name, which it has used for around 10 years. The Land and Geospatial Informatix Corp.’s steering committee met Friday to discu

South Korea’s retail-to-construction conglomerate Lotte is considering acquiring a significant stake in Enzychem Lifesciences to become its second-largest shareholder, a local newspaper reported Monday. The group’s de facto holding firm Lotte Holdings and Lotte Chemical would jointly buy the shares, the report said, which would be the conglomerate’s first attempt at a biotech business. The group is also eyeing a joint venture with Enzychem to further its interest in the f

A South Korean midsized observation satellite was successfully launched into space Monday, the Korean government announced. The Ministry of Science and ICT in Seoul said the 540-kilogram satellite, loaded on Russia’s Soyuz-2.1a rocket, lifted off from Russia’s Baikonur Cosmodrome in Kazakhstan, around 50 days after the satellite arrived at the launch site. 　 The ICT Ministry added that the ground station made its first contact with the satellite 102 minutes after the launch and a

Biotech firm ViGenCell plans to list its shares on the local bourse in the third quarter of this year in an initial public offering, the company said Monday. Commissioned by the bourse operator Korea Exchange, two independent expert groups have recently conducted a review of the company’s biotech assets, growth potential and business operations and have cleared it for the flotation, ViGenCell said. Following the initial approval, the company plans to apply for the Korea Exchange&rsquo

Naver spent 1.33 trillion won ($1.1 billion) in research and development last year, nearly a quarter of its total annual sales, the company said Sunday. Its investment-to-sales ratio of 25.11 percent was the highest among all South Korean companies that release annual performance reports. According to the company’s annual report, its investment in R&D activities was larger than its annual operating profit last year, which was 1.2 trillion won. Compared to a year earlier, the R&D

Posco Group, the world’s fifth-largest steelmaker by output, said Sunday that it would increase investment in future business opportunities, while making efforts to improve corporate governance in announcing its new midterm plan covering the three years from 2021 to 2023. Under the second term of its chairman Choi Jeong-woo, the group expects to see improved outcomes from its key growth businesses, including hydrogen, liquefied natural gas, food and battery materials. The group expects

Samsung BioLogics, the pharmaceutical arm of Samsung Group, vowed Friday to further expand its range of drug products down the road, in a move to grow beyond the conventional antibody drug conjugate business. The blue print was delivered by CEO John Rim during the company’s 10th shareholders meeting held at the headquarters in Incheon. Rim, who was named CEO in December last year, said the company plans to secure related technologies and facilities that are capable of producing cell and

The competition to develop the country’s second COVID-19 treatment continues among South Korea’s major pharmaceutical companies after Chong Kun Dang Pharmaceutical recently dropped out. South Korea’s Ministry of Food and Drug Safety announced Wednesday that it has decided not to approve Chong Kun Dang Pharmaceutical’s candidate, Nafabeltan, based on a review by its advisory board of its efficacy and safety. Chong Kun Dang Pharmaceutical’s acute pancreatitis dru

Daewoong Pharmaceutical said Thursday that the company has out-licensed its gastroesophageal reflux disease agent Fexuprazan to Shanghai Haini Pharmaceutical for 380 billion won. The deal included an upfront payment of 6.8 billion won and 13.6 billion won in milestone payments, the company added. Under the agreement, Shanghai Haini has acquired rights to conduct clinical studies for the agent used to treat a digestive disorder. Shanghai Haini would also be in charge of the entire approval pr

The US Food and Drug Administration will carry out a pre-approval inspection in May at Hanmi Pharmaceutical’s drug manufacturing facilities and packaging sites in Gyeonggi Province’s Pyeongtaek that produces the novel drug Rolontis, the Korean company said Wednesday. The US FDA was slated to approve Hanmi’s manufacturing of the given drug on Oct. 24 last year, but the schedule was temporarily shelved due to restrictions on overseas business trips amid the escalating COVID-19

South Korean biotechnology company Celltrion said Wednesday that the company‘s breast cancer drug Herzuma reached a market share of 44 percent in Japan last year. Herzuma is a biosimilar of Roche’s blockbuster breast cancer drug Herceptin (trastuzumab), used in treating patients with certain breast and gastric cancers. In the third quarter of 2019, the market share of Herzuma in Japan was just 2 percent, but the figure jumped to 12 percent in the following quarter. Herzuma&rsqu

The South Korean government announced that it would spend 595 billion won ($525.6 million) by 2030 to support the country’s regenerative medicine sector. According to the Ministry of Science and ICT, the program will start in July this year, focused on supporting the overall research and development of regenerative medicines, exploration of related business opportunities and out-licensing of technologies. The goal is to help local firms develop at least four new regenerative medicines

South Korea’s data industry grew 14 percent to 19 trillion won ($16.81 billion) last year, according to government data on Tuesday. According to a report from the Ministry of Science and ICT and the Korea Data Agency, the number of professionals in the data industry surpassed 100,000 for the first time. The report said the local data industry had expanded from 16.8 trillion won in 2019 to 19.2 trillion won last year. This figure takes local companies’ sales into account, as well

Hyosung Advanced Materials, the South Korea-based industrial materials producer, said Tuesday that the company would supply its airbags for an Amazon-backed self-driving car. According to Hyosung Advanced Materials, the company’s airbag development unit Global Safety Textiles signed a supply contract with Zoox, the robotaxi company acquired by Amazon for more than $1 billion earlier last year. Under the contract, GST will supply its one-piece woven airbag to Zoox, which is developing

Samsung Bioepis said Monday that the company has signed a marketing partnership with Yuhan to launch its adalimumab biosimilar Adalloce. Adalloce is a pen type biosimilar of Humira, used in treating active autoimmune and inflammatory conditions such as rheumatism, Crohn’s disease and ulcerative colitis. The drug was launched as Imraldi in European countries in 2018 and posted a cumulative $417 million in sales as of last year. In South Korea, Samsung Bioepis will launch the adalimumab bi

Hanmi Pharmaceutical said Friday that its non-small cell lung cancer treatment Poziotinib has received the fast track designation from the US Food and Drug Administration. Hanmi added that its US partner Spectrum Pharmaceuticals would submit the new drug application to the FDA by the end of this year. Fast track designation from the US FDA is one of the measures designed to support development and expedite the review of drugs that show promise in treating serious and address unmet medical ne

SK hynix, South Korea‘s second-largest chipmaker, announced Friday that the company has received approval from the US foreign investment watchdog for acquiring Intel’s NAND business. Upon the approval from the Committee on Foreign Investment in the United States, SK hynix said it has completed all foreign investment screening procedures the US requires. Earlier, the company had obtained the approval of the US Federal Trade Commission, late last year. SK hynix said the company wo

SK Bioscience will develop an all-in-one vaccine targeting COVID-19 variants, together with the Coalition for Epidemic Preparedness Innovations, the South Korean firm said Thursday. SK Bioscience would receive funding from CEPI, worth up to $14.2 million, for the research and development. The South Korean vaccine developer could receive additional funds of as much as $12.5 million for building manufacturing facilities. For the new vaccine, the company hopes to build on its experience with n

The Korea Advanced Institute of Science and Technology’s research team has discovered a new way of treating the movement disorder dystonia, it announced Wednesday. Patients with dystonia suffer from involuntary muscle spasms or contractions, resulting in repetitive movements and abnormal body posture. Led by Professor Kim Dae-so, the research team has found that volinanserin, or MDL100907, has the potential to treat dystonia as an antagonist to 5-HT2AR, a serotonin receptor. According

Daewoong Pharmaceutical’s partner company in the US is to begin a phase two study of using botulinum toxin complex injections as a preventive treatment for migraines, according to the South Korean firm Tuesday. AEON Biopharma, a California-based private clinical-stage biopharmaceutical company, has licensed the ABP-450 injection from Daewoong Pharmaceutical and has exclusive development and distribution rights for ABP-450 in the US, Canada and the European countries. Last year, the US